How long do I need to stay on a GLP-1 medication?

For most patients, GLP-1 therapy is a long-term or indefinite treatment. Obesity is a chronic disease, and the medical consensus from the Obesity Medicine Association and Endocrine Society is that GLP-1 medications should be continued as long as they are effective and well-tolerated — similar to blood pressure or cholesterol medication.

Can I lower my GLP-1 dose after reaching my weight loss goal?

Many prescribers use a lower maintenance dose once patients reach their target. For example, stepping down from semaglutide 2.4 mg to 1.0 mg. Early evidence and clinical experience suggest this preserves most of the weight loss benefit at a lower side effect burden and cost. Discuss this option with your prescriber.

What percentage of weight do people regain after stopping GLP-1s?

The STEP 1 extension trial showed participants regained approximately two-thirds of their lost weight within one year of stopping semaglutide. Most regain occurs in the first 6-9 months. This is why maintenance strategies — whether continued medication, dose reduction, or intensive lifestyle support — are essential.

What lifestyle changes help maintain weight loss on GLP-1 medications?

The strongest evidence supports resistance training 2-3 times per week, 150+ minutes of moderate activity weekly, protein intake of 1.2-1.6 g/kg body weight, weekly weigh-ins, 7-9 hours of sleep, and behavioral support. These habits are easiest to build while still on medication.

Is intermittent GLP-1 dosing effective for weight maintenance?

Intermittent dosing — such as 3 weeks on, 1 week off — is an emerging approach some clinicians are trying, but there is no strong published evidence yet supporting a specific intermittent protocol. If you are interested in this approach, discuss it with your prescriber and monitor your weight closely.

How much does long-term GLP-1 treatment cost?

Costs vary widely. Brand-name injectables list at approximately $1,349/month. Oral options run $149-299/month. Compounded semaglutide is $129-199/month. Medicare Part D is expected to cover GLP-1s at a $50/month copay cap (Bridge program scheduled July 2026). A maintenance dose may also be cheaper than a full therapeutic dose depending on your medication and plan.

Results & Benefits

GLP-1 Maintenance Guide: How to Keep the Weight Off Long-Term

Updated March 28, 2026

Fact CheckedPatient Verified

Complete guide to maintaining weight loss on GLP-1 medications — maintenance dosing strategies, lifestyle habits that stick, when to reduce doses, and preventing the regain trap.

Key Takeaways

STEP 1 extension: approximately two-thirds of lost weight is regained within one year of stopping.
Brand-name injectable GLP-1s list at ~$1,349/month; oral options run $149–299/month.
Medicare Part D Bridge program (July 2026): $50/month copay cap with no step therapy requirement.
Stop semaglutide ≥2 months before planned conception; stop tirzepatide ≥1 month before.
Resistance training 2–3x/week and protein ≥1.2 g/kg/day are the strongest predictors of maintenance.

On this page

Find your match

Answer a few questions and we’ll match you with the right provider and medication.

Take the Quiz →

Free · 2 min · No signup required

GLP-1 Maintenance Guide: How to Keep the Weight Off Long-Term

If you have lost weight on a GLP-1 medication, you have already done the hard part of starting. Now comes the question that determines whether that progress lasts: what is your maintenance plan?

The data is clear — stopping GLP-1 treatment without a strategy leads to significant weight regain for most patients. But this is not a reason for despair. It is a reason to plan. Maintenance is not a sign that treatment failed. It is the treatment working as intended for a chronic condition.

This guide covers the five main maintenance dosing strategies, the lifestyle habits with the strongest evidence, how to manage cost over the long term, and how to work with your prescriber to build a plan that fits your life.

Editorial Independence Note: Telehealth Ally does not accept payment from providers for placement or ranking. Data cited in this guide is drawn from published clinical trials and independent analyses. See our editorial policy for details.

The Regain Reality

Before discussing maintenance strategies, it helps to understand what happens without one.

The STEP 1 extension trial — the most widely cited data on GLP-1 discontinuation — found that participants who stopped semaglutide 2.4 mg regained approximately two-thirds of their lost weight within one year. The SURMOUNT-4 trial showed a similar pattern with tirzepatide: patients who switched to placebo regained about half of their lost weight over the following year.

CNN's 2026 review of long-term GLP-1 outcomes reinforced what the clinical data already showed: most patients who stop treatment regain the majority of their weight within two years.

What These Numbers Actually Mean

Scenario	Without Maintenance	With Maintenance Strategy
Lost 40 lbs on semaglutide	Expect to regain ~27 lbs within 1 year of stopping	Continued treatment or structured step-down preserves most or all of the loss
Lost 60 lbs on tirzepatide	Expect to regain ~30 lbs within 1 year of stopping	SURMOUNT-3/4 data shows sustained loss with continued use
Metabolic improvements	Blood sugar, blood pressure, and lipid improvements largely reverse alongside weight regain	Sustained weight maintenance preserves metabolic benefits

This is not treatment failure. This is evidence that obesity is a chronic disease — the same way blood pressure rising after stopping an antihypertensive is evidence that hypertension is chronic. The treatment effect requires the treatment.

Why Weight Comes Back: The Biology

Understanding the biology makes the maintenance discussion practical rather than discouraging. Weight regain after stopping a GLP-1 is not a character flaw. It is physiology.

Appetite Hormones Reset

GLP-1 medications suppress appetite by mimicking the GLP-1 hormone your gut produces after eating. They also slow gastric emptying and act on brain regions involved in hunger and reward. When you stop the medication, these effects disappear within 2-4 weeks. Your appetite returns to pre-treatment levels — not because you lack discipline, but because the hormonal signals driving hunger are no longer being modulated.

"Food Noise" Returns

Many patients describe one of the most valued effects of GLP-1 treatment as the quieting of "food noise" — the constant mental preoccupation with food. When medication stops, this background hum returns. Patients consistently report this as one of the hardest aspects of discontinuation.

Metabolic Adaptation Persists

After weight loss, your resting metabolic rate is lower than expected for someone of your new size. This is a well-documented survival mechanism. It does not fully resolve after weight stabilization, meaning you burn fewer calories at rest than someone who was always at your current weight. This makes maintenance harder without pharmacological support.

Behavioral Changes Erode

The healthy habits you built while on GLP-1s — smaller portions, protein-first meals, reduced snacking — are easier to maintain when appetite is suppressed. Without that pharmacological foundation, maintaining them requires significantly more effort, and many patients find behavioral gains slipping alongside the medication's effects.

The takeaway: maintenance is not optional for most patients. The question is not whether you need a strategy — it is which strategy fits your situation best.

Maintenance Dosing Options: Five Strategies

There is no single correct approach to GLP-1 maintenance. The right strategy depends on your treatment response, side effect tolerance, insurance coverage, cost situation, and personal preferences. Here are the five main approaches prescribers are using.

1. Stay at Therapeutic Dose

What it is: Continue the same dose that achieved your weight loss — for example, semaglutide 2.4 mg or tirzepatide 15 mg — indefinitely.

The evidence: This approach has the strongest clinical data behind it. The STEP 5 trial followed patients on continuous semaglutide 2.4 mg for two years and showed sustained weight loss of approximately 15%. SURMOUNT-3 and SURMOUNT-4 data for tirzepatide showed similar benefits with continued use.

Best for: Patients with good insurance coverage, manageable side effects, and higher-risk metabolic profiles where maximum weight loss is clinically important.

The tradeoffs: Highest cost and highest side effect burden over time. Some patients experience diminishing side effects with continued use, but GI symptoms, fatigue, or other issues can persist.

2. Step Down to a Lower Maintenance Dose

What it is: Reduce to a lower dose once weight loss goals are met — for example, moving from semaglutide 2.4 mg to 1.0 mg, or from tirzepatide 15 mg to 7.5 mg.

The evidence: There are no large-scale, randomized trials specifically studying step-down maintenance protocols. However, clinical experience and early real-world data suggest that many patients can preserve most of their weight loss at a lower dose, with reduced side effects and potentially lower cost.

Best for: Patients who have reached their target weight and want to reduce side effect burden or cost while maintaining most of their results.

The tradeoffs: Some patients may experience partial regain at the lower dose. Close monitoring is essential — weekly weigh-ins and a clear threshold (typically 3-5% regain) for stepping back up.

3. Intermittent Dosing

What it is: Cycle the medication rather than taking it continuously — for example, three weeks on, one week off, or alternating months.

The evidence: This is the least studied approach. There are no published clinical trials specifically evaluating intermittent GLP-1 dosing for weight maintenance. Some clinicians are trying it based on the logic that periodic medication breaks may reduce side effect burden and cost while providing enough pharmacological support to prevent significant regain.

Best for: Patients exploring cost reduction strategies who are willing to monitor closely and accept the uncertainty of an evidence-light approach.

The tradeoffs: Unknown efficacy. The pharmacokinetics of weekly GLP-1s like semaglutide mean that even a one-week break allows significant drug clearance. This approach should only be attempted with prescriber guidance and close weight monitoring.

4. Medication Switch

What it is: Transition from one GLP-1 formulation or medication to another — for example, from injectable semaglutide to oral semaglutide for convenience, or from one GLP-1 to another for better tolerance.

The evidence: Switching between formulations is common in clinical practice. Oral semaglutide (Rybelsus, oral Wegovy) provides an alternative for patients who want to avoid injections long-term. Switching between GLP-1s (e.g., from semaglutide to tirzepatide or vice versa) is also done when patients plateau or experience side effects.

Best for: Patients who want to stay on treatment but need a different delivery method or are experiencing side effects or diminishing response with their current medication.

The tradeoffs: Each switch requires a retitration period. Oral formulations have specific dosing requirements (empty stomach, 30-minute window before eating or drinking). Insurance coverage may differ between medications.

5. Combination Approach

What it is: Use a lower GLP-1 dose combined with intensive lifestyle intervention and potentially other medications to create a multi-layered maintenance strategy.

The evidence: The combination of pharmacotherapy and structured lifestyle intervention consistently outperforms either approach alone in obesity medicine research. A lower GLP-1 dose plus resistance training, high protein intake, and behavioral support may achieve maintenance comparable to a full therapeutic dose alone.

Best for: Patients who are motivated to invest in lifestyle changes and want to minimize their medication dependence without abandoning pharmacological support entirely.

The tradeoffs: Requires more effort and behavioral commitment. The lifestyle component needs to be genuinely sustained, not aspirational. This approach works best when exercise and nutrition habits are already well-established before the dose reduction.

What the Evidence Says

It is important to be honest about where the evidence is strong and where clinical practice is ahead of the research.

Strong Evidence

Continuous use at therapeutic dose works. The STEP 5 trial (2 years of semaglutide 2.4 mg) and SURMOUNT continuation data show that staying on medication preserves weight loss and metabolic improvements.
Stopping leads to regain. Every discontinuation study — STEP 1 extension, SURMOUNT-4, and real-world analyses — shows significant weight regain after stopping.
Obesity is chronic. The disease model is supported by decades of metabolic research and is endorsed by every major medical organization.

Emerging but Limited Evidence

Lower maintenance doses. Clinical experience suggests this works for many patients, but no large randomized trial has directly compared maintenance at a reduced dose versus full dose versus placebo.
Combination approaches. The logic is sound and consistent with obesity medicine principles, but specific protocols have not been standardized or validated in maintenance-specific trials.
Intermittent dosing. Essentially anecdotal at this point. Clinicians are experimenting, but published data is absent.

What We Do Not Know Yet

The optimal step-down protocol (how fast, to what dose, for whom)
Whether some patients can eventually discontinue medication entirely without regain
Long-term outcomes beyond 2-3 years of continuous use for most GLP-1s
Whether maintenance dosing needs change over time (dose creep, tolerance)

The honest bottom line: staying on treatment has the best evidence. Everything else is a reasonable but evidence-light alternative that requires close monitoring.

The Lifestyle Foundation

Regardless of which dosing strategy you choose, these lifestyle habits form the foundation of long-term maintenance. They are not a replacement for medication for most patients — but they make every strategy work better.

Exercise: The Non-Negotiable

Exercise is the single strongest lifestyle predictor of long-term weight maintenance, and the type of exercise matters.

Resistance training (2-3 times per week): This is the highest priority. GLP-1 medications can accelerate muscle loss alongside fat loss, and muscle mass directly supports your metabolic rate. Resistance training preserves lean mass, improves insulin sensitivity, and supports functional capacity. If you do nothing else, do this.

Moderate aerobic activity (150+ minutes per week): Walking, cycling, swimming, or any activity you will actually do consistently. The National Weight Control Registry — the largest study of long-term weight maintenance — consistently shows that people who maintain significant weight loss exercise regularly, with most averaging 200+ minutes per week.

Daily movement: Steps, active commuting, taking stairs. Non-exercise activity thermogenesis (NEAT) accounts for a larger share of daily calorie expenditure than most people realize.

See our GLP-1 muscle loss guide for detailed protocols on preserving lean mass during and after treatment.

Protein Intake: 1.2-1.6 g/kg

Protein has the highest thermic effect of any macronutrient, meaning your body burns more calories digesting it. It also promotes satiety and supports muscle preservation — all critical during maintenance.

Target the higher end of the range: 1.2-1.6 grams of protein per kilogram of body weight daily. For a 180-pound person, that is approximately 100-130 grams per day. Spread intake across meals for optimal absorption.

Weekly Weigh-Ins

Weigh yourself at the same time, on the same day, once per week. Not daily — daily fluctuations create noise that obscures trends. Weekly weigh-ins give you a reliable signal.

Set a threshold: Establish a specific number — typically 3-5% above your maintenance weight — that triggers a conversation with your prescriber about adjusting your strategy. Having a defined threshold prevents the gradual denial that accompanies slow regain.

Sleep: 7-9 Hours

Sleep deprivation actively opposes the effects of GLP-1 medications. Poor sleep increases ghrelin (the hunger hormone), reduces leptin (the satiety hormone), impairs insulin sensitivity, and makes every other maintenance behavior harder. Seven to nine hours of consistent, quality sleep is not a luxury — it is a physiological requirement for weight maintenance.

Behavioral Support

The mental and emotional dimensions of weight maintenance deserve as much attention as the physical ones.

Therapy or counseling for emotional eating patterns, body image, and the psychological adjustment of weight loss
Support groups — in-person or online communities of people navigating the same challenges
Mindful eating practices — awareness of hunger and fullness signals, which become more important when pharmacological appetite suppression is reduced

Build these supports while you are still on full-dose medication. The window of reduced appetite is the best time to develop coping strategies that do not involve food.

Cost Strategies for Long-Term Use

If GLP-1 therapy is likely long-term, cost becomes a central planning consideration. Here are the current options for managing it.

Insurance Coverage Is Expanding

The insurance landscape for GLP-1 medications has shifted significantly:

Medicare Part D now covers GLP-1s for weight management with a $50/month copay cap (effective April 2026). See our Medicare GLP-1 coverage guide.
Commercial plans are increasingly adding coverage, driven by employer demand and cost-effectiveness data showing reduced cardiovascular events and diabetes progression.
Employer-sponsored plans are adding GLP-1 benefits. If yours does not cover them, ask HR — benefits are typically reviewed annually.

Dose Reduction Can Reduce Cost

A maintenance dose may be cheaper than a therapeutic dose, depending on your medication and insurance plan. Semaglutide 1.0 mg pens are less expensive than 2.4 mg pens. Discuss with your prescriber whether a lower dose is clinically appropriate — the cost savings may be a secondary benefit.

Oral vs. Injectable

Oral semaglutide options run $149-299/month out-of-pocket, compared to approximately $1,349/month list price for brand-name injectable Wegovy. If your insurance does not cover injectables or your copay is high, an oral formulation may be a more sustainable long-term option.

Compounded Options

Compounded semaglutide remains available at $129-199/month through telehealth providers using FDA-regulated compounding pharmacies. Availability may shift as drug shortages resolve and regulatory policies evolve — this is an area to monitor.

Manufacturer Assistance Programs

Novo Nordisk (NovoCare) and Eli Lilly offer income-based patient assistance programs that can reduce costs to $0-25/month for eligible patients. These programs have specific eligibility criteria and are worth exploring if you are paying out of pocket.

See our GLP-1 pricing breakdown and NovoCare guide for detailed cost comparisons.

Working with Your Provider

Maintenance is a collaborative effort between you and your prescriber. Here is how to make that relationship productive.

What to Discuss at Your Maintenance Appointment

Your maintenance goal. Is it staying at your current weight? Losing more? Being realistic about what long-term maintenance looks like for you.
Dosing strategy. Which of the five approaches above makes sense given your response, side effects, insurance, and cost situation?
Monitoring plan. How often will you check in? What triggers warrant an earlier appointment?
Re-intervention threshold. A specific weight or percentage regain that triggers a treatment adjustment. Write it down. Agree on it.
Side effect management. Long-term side effects may differ from acute titration effects. Report new or worsening symptoms.

Red Flags That Warrant an Earlier Visit

Weight regain exceeding your agreed threshold
Return of "food noise" or significant appetite changes
New or worsening side effects
Changes in insurance coverage or ability to afford medication
Plans for pregnancy or surgery

If Your Provider Dismisses Maintenance Concerns

Not all providers have deep expertise in obesity medicine. If your prescriber is not familiar with maintenance dosing strategies or dismisses the need for a long-term plan, consider seeking a second opinion from a board-certified obesity medicine specialist. You can find one through the Obesity Medicine Association's provider directory.

Am I On This Forever?

This is the question behind all the other questions, and it deserves a direct answer.

For most patients: yes, or at least for a very long time. The evidence is consistent that obesity is a chronic condition requiring ongoing management. GLP-1 medications are not a course of treatment you complete — they are a chronic disease management tool, the same way statins manage cholesterol or antihypertensives manage blood pressure.

Why This Is Not Bad News

Framing long-term GLP-1 use as a burden misses the point. Before these medications existed, most people with obesity had no effective long-term treatment at all. Weight loss attempts failed at a 95% rate over 5 years. Now there is a pharmacological tool that works — and continuing to use it is not a failure. It is the treatment succeeding.

The question "will I be on this forever?" implies that needing medication is a problem to solve. For a chronic disease, ongoing treatment is the solution, not the problem.

Some Patients May Be Able to Reduce Over Time

This is not absolute. A subset of patients — particularly those who have made significant lifestyle changes, have strong behavioral support, and are closely monitored — may successfully reduce their dose over time or, in some cases, discontinue with careful supervision.

But the data says these patients are the exception. Plan for long-term use. If you turn out to be someone who can step down, that is a bonus — not the baseline expectation.

The Alternative Carries Its Own Costs

Stopping treatment and regaining weight is not cost-free. Regained weight brings back the cardiovascular risk, the metabolic dysfunction, the joint stress, and the quality-of-life burden that the medication was addressing. When weighing the cost and commitment of long-term GLP-1 use, weigh it against the costs of the alternative.

Special Situations

Pregnancy Planning

GLP-1 medications should be discontinued before conception. Current guidance recommends stopping semaglutide at least 2 months before attempting pregnancy, and tirzepatide at least 6-7 weeks before, due to its longer half-life. If you are planning a pregnancy, discuss timing with both your prescriber and your OB-GYN. Weight management during the pre-conception and postpartum periods will need an alternative strategy.

Surgery

Many anesthesiologists require patients to hold GLP-1 medications before elective surgery due to concerns about delayed gastric emptying and aspiration risk. Current guidance from the American Society of Anesthesiologists recommends holding weekly GLP-1 injections for at least one week before procedures requiring anesthesia. Discuss the timeline with your surgical team and your prescriber, and have a plan for resuming after recovery.

Insurance Changes

If your insurance coverage changes — whether through a job change, plan modification, or policy shift — act before your current supply runs out. Options include:

Filing a prior authorization with your new plan immediately
Requesting a bridge supply from your current prescriber
Exploring manufacturer patient assistance programs
Considering a temporary switch to a lower-cost formulation (compounded or oral) while coverage is resolved

Do not simply stop taking your medication because of an insurance gap. A lapse in treatment triggers the same regain biology as intentional discontinuation.

Medication Shortages

GLP-1 supply chain issues have affected patients intermittently. If your medication is unavailable:

Ask your pharmacy about expected restock dates
Check whether an alternative dose or formulation of the same medication is in stock
Discuss a temporary switch to a different GLP-1 with your prescriber
If a gap is unavoidable, intensify your lifestyle interventions during the interruption and resume as soon as possible

Frequently Asked Questions

How long should I plan to take a GLP-1 medication?

Plan for long-term use — years, not months. The medical consensus treats obesity as a chronic condition requiring ongoing management. Some patients may be able to reduce their dose over time, but the baseline expectation should be indefinite treatment, with periodic reassessment.

What is a maintenance dose?

A maintenance dose is a lower dose of your GLP-1 medication used after you have reached your weight loss goal. For example, stepping down from semaglutide 2.4 mg (the maximum weight-loss dose) to 1.0 mg. The goal is to preserve most of the weight loss benefit while reducing side effects and potentially cost.

Will my weight loss plateau on long-term GLP-1 therapy?

Most patients reach a weight plateau at some point during treatment, typically between 12-18 months. This is normal and does not mean the medication has stopped working — it means you have reached a new equilibrium. The medication is still preventing regain even if it is no longer producing additional loss.

Can I take breaks from my GLP-1 medication?

Breaks are not well-studied. Any period without medication will reduce the drug's appetite-suppressing effects, and weight regain can begin within weeks. If you are considering a break — whether for cost, side effects, or personal reasons — discuss it with your prescriber and have a monitoring plan.

What happens if I regain weight while still on medication?

Some patients experience gradual weight regain even while continuing treatment. This can happen due to metabolic adaptation, behavioral drift, or other factors. If you are regaining weight on your current dose, discuss options with your prescriber — these may include dose adjustment, adding an exercise or nutrition intervention, or switching medications.

Is there a risk to taking GLP-1s long-term?

The longest published safety data for semaglutide extends to approximately 4 years (SELECT trial). For tirzepatide, long-term data beyond 2-3 years is more limited. No major safety signals have emerged from longer-term use, but this is an area of ongoing monitoring. Discuss your individual risk profile with your prescriber at regular intervals.

Can I switch from a brand-name GLP-1 to a cheaper option for maintenance?

Yes. Options include switching from injectable to oral formulations, from brand-name to compounded versions, or from one GLP-1 to another based on cost and insurance coverage. Any switch should be done in coordination with your prescriber.

What Happens When You Stop Taking GLP-1 Medications — The full weight regain data and discontinuation strategies
GLP-1 Muscle Loss Research Guide — Lean mass data, prevention strategies, and exercise protocols
GLP-1 Pricing Breakdown by Provider — Full cost comparison to find the most affordable long-term option
GLP-1 Food Aversion Guide — Managing taste changes, food preferences, and appetite shifts on GLP-1s
GLP-1 Exercise Performance Guide — How GLP-1 medications affect exercise capacity and workout strategies
GLP-1 Adherence and Retention Guide — What the research says about staying on treatment
Medicare GLP-1 Coverage Guide — New Part D coverage details and enrollment

Last verified: April 2026. Clinical data cited in this guide draws from the STEP 1 extension (Wilding et al., 2022), STEP 5 (2-year semaglutide data), SURMOUNT-3 and SURMOUNT-4 (tirzepatide maintenance and discontinuation data), and published obesity medicine guidelines. Maintenance dosing protocols reflect clinical practice patterns and are not yet standardized in published trials. Individual outcomes depend on treatment duration, dosing strategy, lifestyle factors, and patient-specific biology. This guide is for informational purposes and does not replace individual medical advice.

Related Comparisons

Amazon Clinic vs Ro Health for GLP-1 Weight Loss: Big Tech vs Dedicated Program

Amazon Clinic vs Ro Health for GLP-1: retail giant pharmacy access vs dedicated weight loss program. Pricing, clinical depth, and medication access compared. April 2026.

Amazon One Medical vs PlushCare for GLP-1 Weight Loss: Which Is Better?

Amazon One Medical vs PlushCare head-to-head comparison for GLP-1 weight loss — pricing, medications, clinical approach, and whether a hybrid model beats pure telehealth.

Calibrate vs Ro: GLP-1 Weight Loss Programs Compared (2026)

Calibrate vs Ro — year-long structured program vs fast cash-pay access. Which GLP-1 platform is right for you? Side-by-side comparison of cost, program depth, and approach. April 2026.

GLP-1 Maintenance Guide: How to Keep the Weight Off Long-Term

Key Takeaways

GLP-1 Maintenance Guide: How to Keep the Weight Off Long-Term

The Regain Reality

What These Numbers Actually Mean

Why Weight Comes Back: The Biology

Appetite Hormones Reset

"Food Noise" Returns

Metabolic Adaptation Persists

Behavioral Changes Erode

Maintenance Dosing Options: Five Strategies

1. Stay at Therapeutic Dose

2. Step Down to a Lower Maintenance Dose

3. Intermittent Dosing

4. Medication Switch

5. Combination Approach

What the Evidence Says

Strong Evidence

Emerging but Limited Evidence

What We Do Not Know Yet

The Lifestyle Foundation

Exercise: The Non-Negotiable

Protein Intake: 1.2-1.6 g/kg

Weekly Weigh-Ins

Sleep: 7-9 Hours

Behavioral Support

Cost Strategies for Long-Term Use

Insurance Coverage Is Expanding

Dose Reduction Can Reduce Cost

Oral vs. Injectable

Compounded Options

Manufacturer Assistance Programs

Working with Your Provider

What to Discuss at Your Maintenance Appointment

Red Flags That Warrant an Earlier Visit

If Your Provider Dismisses Maintenance Concerns

Am I On This Forever?

Why This Is Not Bad News

Some Patients May Be Able to Reduce Over Time

The Alternative Carries Its Own Costs

Special Situations

Pregnancy Planning

Surgery

Insurance Changes

Medication Shortages

Frequently Asked Questions

How long should I plan to take a GLP-1 medication?

What is a maintenance dose?

Will my weight loss plateau on long-term GLP-1 therapy?

Can I take breaks from my GLP-1 medication?

What happens if I regain weight while still on medication?

Is there a risk to taking GLP-1s long-term?

Can I switch from a brand-name GLP-1 to a cheaper option for maintenance?

Related Reading

Related Comparisons

Amazon Clinic vs Ro Health for GLP-1 Weight Loss: Big Tech vs Dedicated Program

Amazon One Medical vs PlushCare for GLP-1 Weight Loss: Which Is Better?

Calibrate vs Ro: GLP-1 Weight Loss Programs Compared (2026)

More Guides

Does Aetna Cover GLP-1 Medications? 2026 Coverage Guide

Aleniglipron: Structure Therapeutics' Oral GLP-1 — What Patients Need to Know

Amycretin (Zenagamtide): Novo Nordisk's Next-Gen GLP-1/Amylin Agonist

AOD-9604 for Weight Loss: Telehealth Providers Guide 2026

Best GLP-1 Medication 2026: Every Approved Option Ranked by Use Case

Which GLP-1 Has the Fewest Side Effects? A Medication-by-Medication Comparison

Best GLP-1 Options After Foundayo Approval: Oral vs Injectable 2026

Best GLP-1 Pill Options in 2026: Oral Wegovy, Orforglipron & More

Best Oral GLP-1 Options 2026: Foundayo vs Rybelsus Complete Comparison

Best GLP-1 Under $200 Per Month: 2026 Budget Guide

Best GLP-1 Weight Loss Programs 2026: Every Major Provider Ranked

Best Growth Hormone Peptide Providers Online: 2026 Independent Comparison

Best Online HRT 2026: Telehealth Menopause Treatment Platforms Compared

Best Online TRT Clinics 2026: Telehealth Testosterone Replacement Compared

Best Oral GLP-1 Options in 2026: Every Pill Compared

Best Telehealth Providers for Tirzepatide 2026: Ranked by Price and Care

Best Weight Loss Injection 2026: Wegovy HD, Zepbound, and Every Option Compared

Best Weight Loss Medication 2026: Every FDA-Approved Option Ranked

Does Blue Cross Blue Shield Cover GLP-1 Medications? 2026 Guide

Best BPC-157 Telehealth Providers 2026: Complete Guide

BPC-157 vs TB-500: Which Injury Recovery Peptide Is Right for You?